Circulating C-reactive protein and breast cancer risk-systematic literature review and meta-analysis of prospective cohort studies

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 10, 2015, Pages 1439-1449

  Chan, Doris S M ^a   Bandera, Elisa V ^b   Greenwood, Darren C ^c   Norat, Teresa ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; TUMOR MARKER;

BODY MASS; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; FOLLOW UP; HUMAN; LIFESTYLE; MEDLINE; META ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; BLOOD; BREAST NEOPLASMS; FEMALE; HEALTH; INFLAMMATION; METABOLISM; MORBIDITY; RISK FACTOR;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; GLOBAL HEALTH; HUMANS; INFLAMMATION; MORBIDITY; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84942873857     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-0324     Document Type: Review

References (48)

1. Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 2011;48:155-70.
2. Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part2. Clin Chem 2001;47:418-25.
3. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated Creactive protein levels in overweight and obese adults. JAMA 1999;282:2131-5.
4. Bermudez EA, Rifai N, Buring JE, Manson JE, Ridker PM. Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol 2002;89:1117-9.
5. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713-6.
6. Ford ES. Does exercise reduce inflammation? Physical activity and Creactive protein among U.S. adults. Epidemiology 2002;13:561-8.
7. Dias JA, Wirfalt E, Drake I, Gullberg B, Hedblad B, Persson M, et al. A high quality diet is associated with reduced systemic inflammation in middleaged individuals. Atherosclerosis 2015;238:38-44.
8. Stewart SH, Mainous AG III, Gilbert G. Relation between alcohol consumption and C-reactive protein levels in the adult US population. J Am Board Fam Pract 2002;15:437-42.
9. Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and inflammation: new insights into breast cancer development and progression. Am Soc Clin Oncol Educ Book 2013;46-51.
10. Trinchieri G. Cancer and inflammation: An old intuition with rapidly evolving new concepts. Annu Rev Immunol 2012;30:677-706.
11. Kaptoge S, Di AE, Lowe G, Pepys MB, Thompson SG, Collins R, et al. Creactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. Lancet 2010;375: 132-40.
12. Zhou B, Shu B, Yang J, Liu J, Xi T, Xing Y. C-reactive protein, interleukin-6 and the risk of colorectal cancer: A meta-analysis. Cancer Causes Control 2014;25:1397-405.
13. Zhou B, Liu J, Wang ZM, Xi T. C-reactive protein, interleukin 6 and lung cancer risk: A meta-analysis. PLoS One 2012;7:e43075.
14. Han Y, Mao F, WuY, Fu X, Zhu X, Zhou S, et al. Prognostic role of C-reactive protein in breast cancer: A systematic review and meta-analysis. Int J Biol Markers 2011;26:209-15.
15. Hong T, Liu A, Cai D, Zhang Y, Hua D, Hang X, et al. Preoperative serum Creactive protein levels and early breast cancer by BMI and menopausal status. Cancer Invest 2013;31:279-85.
16. Guo YZ, Pan L, Du CJ, Ren DQ, Xie XM. Association between C-reactive protein and risk of cancer: A meta-analysis of prospective cohort studies. Asian Pac J Cancer Prev 2013;14:243-8.
17. Dossus L, Jimenez-Corona A, Romieu I, Boutron-Ruault MC, Boutten A, Dupre T, et al. C-reactive protein and postmenopausal breast cancer risk: results from the E3N cohort study. Cancer Causes Control 2014; 25:533-9.
18. Gaudet MM, Patel AV, Teras LR, Sun J, Campbell PT, Stevens VL, et al. Obesity-related markers and breast cancer in CPS-II Nutrition Cohort. Int J Mol Epidemiol Genet 2013;4:156-66.
19. Ollberding NJ, Kim Y, Shvetsov YB, Wilkens LR, Franke AA, Cooney RV, et al. Prediagnostic leptin, adiponectin, C-reactive protein, and the risk of postmenopausal breast cancer. Cancer Prev Res 2013;6:188-95.
20. Prizment AE, Folsom AR, Dreyfus J, Anderson KE, Visvanathan K, Joshu CE, et al. Plasma C-reactive protein, genetic risk score, and risk of common cancers in the Atherosclerosis Risk in Communities study. Cancer Causes Control 2013;24:2077-87.
21. Touvier M, Fezeu L, Ahluwalia N, Julia C, Charnaux N, Sutton A, et al. Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: A nested case-control study. Am J Epidemiol 2013;177:3-13.
22. Wang G, Li N, Chang S, Bassig BA, Guo L, Ren J, et al. A Prospective Followup Study of the Relationship between C-Reactive Protein and Human Cancer Risk in the Chinese Kailuan Female Cohort. Cancer Epidemiol Biomarkers Prev 2015;24:459-65.
23. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009;6:e1000097.
24. Der Simonian R, Laird N.Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
25. Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata J 2006;6:40-57.
26. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992;135:1301-9.
27. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
28. Sterne JA, Gavaghan D, Egger M. Publication and related bias in metaanalysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000;53:1119-29.
29. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999;28: 964-74.
30. Bagnardi V, Zambon A, Quatto P, Corrao G. Flexible meta-regression functions for modeling aggregate dose-response data, with an application to alcohol and mortality. Am J Epidemiol 2004;159:1077-86.
31. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009;27:2217-24.
32. Amir E, Cecchini RS, Ganz PA, Costantino JP, Beddows S, Hood N, et al. 25- Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. Breast Cancer Res Treat 2012;133:1077-88.
33. Heikkila K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009;20:15-26.
34. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005;14:2413-8.
35. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: The Rotterdam Study. J Clin Oncol 2006; 24:5216-22.
36. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: A prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006;15:381-4.
37. Van Hemelrijck M, Holmberg L, Garmo H, Hammar N, Walldius G, Binda E, et al. Association between levels of C-reactive protein and leukocytes and cancer: Three repeated measurements in the Swedish AMORIS study. Cancer Epidemiol Biomarkers Prev 2011;20:428-37.
38. Zeleniuch-Jacquotte A, Gu Y, Bruning PF, Bonfrer JM, Koenig KL, Arslan AA, et al. Re: C-reactive protein and risk of breast cancer. J Natl Cancer Inst 2008;100:443-4.
39. Zhang SM, Lin J, Cook NR, Lee IM, Manson JE, Buring JE, et al. C-reactive protein and risk of breast cancer. J Natl Cancer Inst 2007;99:890-4.
40. Zhang SM, Ridker PM. Response: Re: C-reactive protein and risk of breast cancer. J Natl Cancer Inst 2008;100:444-5.
41. de Pedro M, Baeza S, Escudero MT, Dierssen-Sotos T, Gomez-Acebo I, Pollan M, et al. Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: A meta-analysis. Breast Cancer Res Treat 2015;149:525-36.
42. Allin KH, Nordestgaard BG, Zacho J, Tybjaerg-Hansen A, Bojesen SE. Creactive protein and the risk of cancer: A mendelian randomization study. J Natl Cancer Inst 2010;102:202-6.
43. Connor AE, Baumgartner RN, Baumgartner KB, Pinkston CM, Boone SD, John EM, et al. Associations between ALOX, COX, and CRP polymorphisms and breast cancer among Hispanic and non-Hispanic white women: The breast cancer health disparities study. Mol Carcinog 2014. doi:10.1002/mc.22228.
44. Heikkila K, Silander K, Salomaa V, Jousilahti P, Koskinen S, Pukkala E, et al. C-reactive protein-associated genetic variants and cancer risk: findings from FINRISK 1992, FINRISK 1997 and Health 2000 studies. Eur J Cancer 2011;47:404-12.
45. Zhang Y, Jiang L. CRP 1059 G/C and 1846G/A polymorphisms and cancer risk: A meta-analysis of 26, 634 subjects. Clin Res Hepatol Gastroenterol 2014;38:607-12.
46. Thompson R, Bandera E, Burley V, Cade J, Forman D, Freudenheim J, et al. Reproducibility of systematic literature reviews on food, nutrition, physical activity and endometrial cancer. Public Health Nutr 2008;11: 1006-14.
47. Myers GL, Rifai N, Tracy RP, Roberts WL, Alexander RW, Biasucci LM, et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease: Application to clinical and public health practice: report from the laboratory science discussion group. Circulation 2004;110: e545-e549.
48. Platz EA, Sutcliffe S, De Marzo AM, Drake CG, Rifai N, Hsing AW, et al. Intra-individual variation in serum C-reactive protein over 4 years: An implication for epidemiologic studies. Cancer Causes Control 2010;21: 847-51.